Bristol Myers Squibb (BMS) said that the phase 3 True North clinical trial evaluating Zeposia (ozanimod) in adult patients with moderate to severe ulcerative colitis (UC) met both primary endpoints. The placebo-controlled late stage trial featuring 645 patients assessed oral Zeposia as an induction and maintenance therapy for the chronic inflammatory bowel disease (IBD). ZEPOSIA […]
Bristol-Myers Squibb has reached a definitive agreement to acquire Celgene Corporation in a monumental cash-and-stock deal worth approximately $74 billion. This acquisition will merge two pharmaceutical giants into a specialty biopharma company focused on cutting-edge therapies for cancer, cardiovascular disease, and immunological conditions. Details of the Bristol-Myers Squibb Celgene merger Under the terms of the […]
